Program
reproxalap
Also written as “Reproxalap Ophthalmic Solution (0.25%)”, “Reproxalap Ophthalmic Solution (0.5%)” and “ADX-102 Ophthalmic Solution (0.5%)”.
Its studies are mostly in Dry Eye Syndromes · Conjunctivitis, Allergic · Alopecia Areata · Uveitis, Anterior, led by 2 companies.
Drug pageReproxalap: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aldeyra Therapeuticsits history only | 200 open or running | phase 3since Apr 4, 2017 | Dec 14, 2016 | none ahead |
| Aldena Therapeuticsits history only | 11 open or running | phase 2since Jan 22, 2025 | Jan 22, 2025 | Nov 2026phase 2 · NCT06826196 |
Also a collaborator on its studies: ORA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 7 earlier studies, Dec 14, 2016 to Aug 31, 2018.
- Jun 9, 2018Named reproxalapINNProposed as its International Nonproprietary Name in WHO's List 119
- Oct 3, 2018Phase 2 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT03709121 · 70 enrolled · Canada
- Mar 15, 2019Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT03879863 · 422 enrolled · United States
- Dec 19, 2019Phase 3 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT04207736 · 95 enrolled · Canada
- Dec 14, 2020Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04674358 · 329 enrolled · United States
- Jan 25, 2021Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04735393 · 757 enrolled · United States
- Jul 12, 2021Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04971031 · 158 enrolled · United States
- Sep 13, 2021Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05062330 · 361 enrolled · United States
- Oct 18, 2021Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05102409 · 56 enrolled · Canada
- Feb 1, 2022Phase 3 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT05234554 · 131 enrolled · Canada
- Jun 15, 2022Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05424549 · 63 enrolled · Canada
- Apr 25, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06389214 · 132 enrolled · Canada
- May 17, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06424444 · 421 enrolled · United States
- Jul 2, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06493604 · 116 enrolled · United States
- Jan 22, 2025Aldena Therapeutics’ first study: phase 2 study in Alopecia AreataNew to Aldena TherapeuticsAldena Therapeutics · NCT06826196 · 9 enrolled · United States, Canada
Ahead
- Nov 2026Primary completion: phase 2 study in Alopecia AreataAldena Therapeutics · NCT06826196
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06826196Alopecia Areata · United States, Canada | 2 | Active, not recruiting | Aldena Therapeutics | Nov 2026 | 9 |
| NCT06493604Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Feb 27, 2025 | 116 |
| NCT06424444Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Nov 3, 2024 | 421 |
| NCT06389214Dry Eye Syndromes · Canada | 3 | Completed | Aldeyra Therapeutics | Jun 11, 2024 | 132 |
| NCT05424549Dry Eye Syndromes · Canada | 2 | Completed | Aldeyra Therapeutics | May 9, 2022 | 63 |
| NCT05234554Conjunctivitis, Allergic · Canada | 3 | Completed | Aldeyra Therapeutics | Apr 22, 2023 | 131 |
| NCT05102409Dry Eye Syndromes · Canada | 2 | Completed | Aldeyra Therapeutics | Oct 25, 2021 | 56 |
| NCT05062330Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Mar 4, 2022 | 361 |
| NCT04971031Dry Eye Syndromes · United States | 2 | Completed | Aldeyra Therapeutics | Sep 8, 2021 | 158 |
| NCT04735393Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Oct 11, 2022 | 757 |
| NCT04674358Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Sep 12, 2021 | 329 |
| NCT04207736Conjunctivitis, Allergic · Canada | 3 | Completed | Aldeyra Therapeutics | Feb 16, 2021 | 95 |
| NCT03879863Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Oct 4, 2019 | 422 |
| NCT03709121Conjunctivitis, Allergic · Canada | 2 | Completed | Aldeyra Therapeutics | Mar 20, 2019 | 70 |
| NCT03660878Conjunctivitis, Allergic · United States | 2 | Completed | Aldeyra Therapeutics | Nov 19, 2019 | 52 |
| NCT03494504Conjunctivitis, Allergic · United States | 3 | Completed | Aldeyra Therapeutics | Nov 5, 2018 | 318 |
| NCT03445650Sjogren-Larsson Syndrome · United States | 3 | Completed | Aldeyra Therapeutics | Jan 18, 2020 | 11 |
| NCT03404115Dry Eye Syndromes · United States | 2 | Completed | Aldeyra Therapeutics | Jul 11, 2018 | 300 |
| NCT03162783Dry Eye Syndromes · United States | 2 | Completed | Aldeyra Therapeutics | Jul 6, 2017 | 51 |
| NCT03131154Non-infectious Anterior Uveitis · United States | 3 | Completed | Aldeyra Therapeutics | Apr 19, 2019 | 123 |
| NCT03012165Conjunctivitis, Allergic · United States | 2 | Completed | Aldeyra Therapeutics | May 2017 | 154 |
How it is read
Names in the registry
- “Reproxalap Ophthalmic Solution (0.25%)”, 15 entries
- “Reproxalap Ophthalmic Solution (0.5%)”, 3 entries
- “ADX-102 Ophthalmic Solution (0.5%)”, 2 entries
- “ALD-102 Solution”, 1 entry
- “Reproxalap ophthalmic solution (0.25%)”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 12 studies
- Conjunctivitis, Allergic, 6 studies
- Alopecia Areata, 1 study
- Uveitis, Anterior, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.